Orchestra BioMed

OBIOPre-clinical

Orchestra BioMed is a publicly traded biomedical innovation company focused on developing high-impact therapeutic solutions for mature medical device markets with significant unmet needs. The company employs a partnership-enabled business model, forging strategic collaborations with leading medical device companies to drive global commercialization. Its two flagship technologies target hypertension and atherosclerotic artery disease, two of the world's leading causes of mortality, with late-stage product candidates designed for rapid adoption and strategic value creation.

Market Cap

$271.5M

OBIO · Stock Price

USD 4.645.26 (-53.13%)

Historical price data

AI Company Overview

Technology Platform

Develops transformative therapeutic products for procedure-based medicine, with core platforms in bioelectronic modulation (AVIM Therapy for hypertension) and targeted drug delivery (Virtue SAB for extended-release sirolimus infusion during angioplasty without a permanent implant).

Funding History

Total raised: $170M

IPO$60MUndisclosedJan 26, 2023

Series B$80MDeerfield ManagementJun 15, 2021

Series A$30MMedtronicJun 15, 2018

Opportunities

Orchestra BioMed's primary growth opportunities lie in successfully commercializing its two late-stage platforms through strategic partnerships.

AVIM Therapy targets the massive, comorbid hypertension and pacemaker market, while Virtue SAB addresses high-unmet-need niches within the multi-billion dollar interventional cardiology and peripheral vascular markets.

Successful adoption could position the company as a leader in innovative, procedure-based solutions for chronic cardiovascular diseases.

Risk Factors

Key risks include clinical trial failure or regulatory rejection for its lead candidates, inability to secure crucial strategic partnerships needed for its business model, and failure to achieve market adoption against established, lower-cost competitors.

As a pre-revenue company, it also faces significant financial risk and potential dilution from the need to raise additional capital.

Competitive Landscape

AVIM Therapy competes with pharmaceutical antihypertensives and other device-based therapies, differentiating via integration into pacemakers. Virtue SAB competes with Drug-Eluting Stents and Drug-Coated Balloons, aiming to differentiate by delivering sirolimus without a balloon coating or permanent implant, offering potential cost and procedural advantages.